Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Blinded, Positive-controlled Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in Population Aged 18 Years and Above

NCT05552573 is registered in ClinicalTrials.gov with Guangzhou Patronus Biotech Co., Ltd. as lead sponsor.

NCT NCT05552573
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05552573 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Blinded, Positive-controlled Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in Population Aged 18 Years and Above
Lead sponsor
Guangzhou Patronus Biotech Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
July 19, 2022
Completion date
December 1, 2023
Enrollment
100 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19